DRD2 and Timothy syndrome: Clinical evidence demonstrates that D2R-targeting agents effectively alleviate TS symptoms, confirming that the modulation of striatal dopaminergic signaling—particularly D2R function—represents a core therapeutic strategy for TS (13).